date,title,source
Oct-22-18,Mirati Shares Fall After Cancer Trial Progress Report,TheStreet.com
Oct-22-18,Why Mirati Therapeutics Inc. Is Plunging Today,Motley Fool
Oct-22-18,Mirati Therapeutics stock drops 19.5% after cancer trial results,MarketWatch
Oct-22-18,Mirati Therapeutics Presents Updated Positive Clinical Data From Sitravatinib Immuno-Oncology Combination Trial At ESMO 2018 Congress And Announces FDA Guidance For Registration Trial,PR Newswire
